Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Pittsburgh, Pennsylvania

This page shows live ClinicalTrials.gov search results for Pittsburgh, Pennsylvania, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
10627
Shown on this page
12
Current sort
Recently updated
Location scope
Pittsburgh, PA
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Pittsburgh, Pennsylvania. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 373–384 of 10,627 matching trials in Pittsburgh, PA.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Pittsburgh

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Terminated Phase 1Phase 2 Interventional Results available

Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer

NCT03371979
View directory record Official record
Conditions
Small-cell Lung Cancer
Interventions
Pegzilarginase, Pembrolizumab
Drug
Lead sponsor
Immedica Pharma AB
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
21
States / cities
Mobile, Alabama • Aurora, Colorado • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 7, 2026, 10:17 AM EST
Recruiting Phase 1 Interventional

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria

NCT07241234
View directory record Official record
Conditions
Phenylketonuria
Interventions
AG-181
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Indianapolis, Indiana • Pittsburgh, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 7, 2026, 10:17 AM EST
Recruiting Phase 2 Interventional

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

NCT04981509
View directory record Official record
Conditions
Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Sporadic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Atezolizumab, Bevacizumab, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Computed Tomography with Contrast, Erlotinib, Magnetic Resonance Imaging, Positron Emission Tomography, Sodium Fluoride F-18
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
13
States / cities
La Jolla, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 7, 2026, 10:17 AM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

NCT05595642
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Astegolimab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 80 Years
Enrollment
1,380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
53
States / cities
Birmingham, Alabama • Dothan, Alabama • Glendale, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 7, 2026, 10:17 AM EST
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis

NCT06586112
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Envudeucitinib, Apremilast, Placebo
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
18 Years and older
Enrollment
912 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
55
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Rogers, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 7, 2026, 10:17 AM EST
Completed Phase 3 Interventional Results available

Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children

NCT03859700
View directory record Official record
Conditions
Peanut Allergy
Interventions
DBV712 250 mcg
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
2 Years to 5 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
26
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 7, 2026, 10:17 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

NCT03075696
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Glofitamab, Obinutuzumab, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
6
States / cities
Ann Arbor, Michigan • St Louis, Missouri • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 7, 2026, 10:17 AM EST
Active, not recruiting Phase 2 Interventional

A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)

NCT06924970
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Tebapivat, Tebapivat Matched Placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
16 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Farmington, Connecticut • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 7, 2026, 10:17 AM EST
Terminated Phase 1Phase 2 Interventional Results available

A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study

NCT02875548
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Synovial Sarcoma, Epithelioid Sarcoma (ES), Mesothelioma, Advanced Solid Tumors, Renal Medullary Carcinoma, Non-Hodgkin Lymphoma (NHL)
Interventions
Tazemetostat
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
11
States / cities
Tucson, Arizona • Santa Fe, California • Port Saint Lucie, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 7, 2026, 10:17 AM EST
Active, not recruiting Phase 3 Interventional

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

NCT06238622
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Interventions
Nerandomilast
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
58
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 7, 2026, 10:17 AM EST
Recruiting Phase 3 Interventional

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

NCT07472517
View directory record Official record
Conditions
Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Interventions
obrixtamig, atezolizumab, carboplatin, etoposide
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
16
States / cities
Mobile, Alabama • Little Rock, Arkansas • Hialeah, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 7, 2026, 10:17 AM EST
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Solrikitug in Participants With COPD (ZION)

NCT06496620
View directory record Official record
Conditions
COPD
Interventions
Biological: Solrikitug low dose, Biological: Solrikitug high dose, Placebo
Biological · Other
Lead sponsor
Uniquity One (UNI)
Industry
Eligibility
40 Years to 75 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
94
States / cities
Birmingham, Alabama • Sheffield, Alabama • Peoria, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 7, 2026, 10:17 AM EST